AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21998319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction analysis of 34 genes
Number of subjects: 26
Study 18292453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehydration with 10 mL/kg of lactated Ringer's solution
Number of subjects: 68
Study 18292453 — intervention group
Group type: COMPARATOR
Intervention: Nonprehydration
Number of subjects: 68
Study 16531162 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/30EE
Number of subjects: 75
Study 16531162 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/20EE
Number of subjects: 75
Study 16531162 — intervention group
Group type: COMPARATOR
Intervention: DSG/30EE
Number of subjects: 75
Study 14566163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 79
Study 14566163 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 79
Study 11094598 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1
Number of subjects: 45
Study 11094598 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 micrograms kg‐1
Number of subjects: 45
Study 11094598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8931648 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone 0.05 IU/kg/d
Number of subjects: 31
Study 8931648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8093338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 0
Study 8093338 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 0
Study 3739236 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving sinusoidal grating with random contrast levels (5 to 82%)
Number of subjects: 0
Study 3739236 — intervention group
Group type: EXPERIMENTAL
Intervention: Random changes in temporal frequency (2.25 to 8.25 Hz)
Number of subjects: 0
Study 29574763 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air-polishing (GPAP)
Number of subjects: 27
Study 29574763 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) and air flushing with water (Control)
Number of subjects: 27
Study 27167981 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARM intervention (three-session GE+FP counseling)
Number of subjects: 1081
Study 27167981 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1081
Study 24962711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheburane(®) (Sodium Phenylbutyrate) taste-masked granules
Number of subjects: 0
Study 22893691 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR exposure
Number of subjects: 66
Study 22893691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 21091062 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 times per week)
Number of subjects: 245
Study 21091062 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 times per week)
Number of subjects: 245
Study 18723899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 49
Study 15902121 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-microg buccal misoprostol
Number of subjects: 352
Study 15902121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 12626972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroster HME (changed once a week)
Number of subjects: 2
Study 12626972 — intervention group
Group type: COMPARATOR
Intervention: Hygrobac HME (used for 1 week without change)
Number of subjects: 2
Study 10489664 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron administration before and 4 days after cisplatin treatment
Number of subjects: 98
Study 10489664 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration after tropisetron before cisplatin treatment
Number of subjects: 98
Study 9772614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumigation and inhalation of Huayin Powder
Number of subjects: 39
Study 9772614 — intervention group
Group type: COMPARATOR
Intervention: Composite Qingdaiwan
Number of subjects: 39
Study 1833088 — intervention group
Group type: EXPERIMENTAL
Intervention: GR32191B (80 mg orally before angioplasty and 80 mg/day orally for 6 months)
Number of subjects: 522
Study 1833088 — intervention group
Group type: COMPARATOR
Intervention: Control (250 mg i.v. aspirin before angioplasty and placebo for 6 months)
Number of subjects: 522
Study 1833088 — intervention group
Group type: EXPERIMENTAL
Intervention: GR32191B
Number of subjects: 522
Study 1833088 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 522
Study 6349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial synchronous pacing
Number of subjects: 13
Study 6349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological pacing mode
Number of subjects: 13
Study 6349666 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 13
Study 30968181 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral stenting
Number of subjects: 72
Study 30968181 — intervention group
Group type: COMPARATOR
Intervention: Bilateral stenting
Number of subjects: 72
Study 30147355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 150 mg/day
Number of subjects: 803
Study 30147355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 300 mg/day
Number of subjects: 803
Study 30147355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 450 mg/day
Number of subjects: 803
Study 30147355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 30147355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone (combined groups)
Number of subjects: 803
Study 26615874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning (summative assessment)
Number of subjects: 493
Study 26615874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lectures (summative assessment)
Number of subjects: 493
Study 26615874 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group peer-teaching (summative assessment)
Number of subjects: 493
Study 26615874 — intervention group
Group type: COMPARATOR
Intervention: Self-directed learning (formative assessment)
Number of subjects: 493
Study 26615874 — intervention group
Group type: COMPARATOR
Intervention: Lectures (formative assessment)
Number of subjects: 493
Study 26615874 — intervention group
Group type: COMPARATOR
Intervention: Small-group peer-teaching (formative assessment)
Number of subjects: 493
Study 24374263 — intervention group
Group type: EXPERIMENTAL
Intervention: NBCA (Histoacryl)
Number of subjects: 83
Study 24374263 — intervention group
Group type: EXPERIMENTAL
Intervention: NBCA‐MS (Glubran2)
Number of subjects: 83
Study 24374263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 83
Study 22196510 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy to CV4 and CV8 for 4 weeks (administered three times per week)
Number of subjects: 45
Study 22196510 — intervention group
Group type: COMPARATOR
Intervention: Simulated burning of moxibustion (control group)
Number of subjects: 45
Study 18804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm A.
Number of subjects: 49
Study 18804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm B.
Number of subjects: 49
Study 17710798 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 88
Study 17710798 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 88
Study 17710798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 15071401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin (epoprostenol sodium) at 30 ng x kg x min
Number of subjects: 14
Study 15071401 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized normal saline (placebo)
Number of subjects: 14
Study 11761344 — intervention group
Group type: EXPERIMENTAL
Intervention: High imagers (imagery ability)
Number of subjects: 176
Study 11761344 — intervention group
Group type: COMPARATOR
Intervention: Low imagers (imagery ability)
Number of subjects: 176
Study 11761344 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 176
Study 11761344 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation condition
Number of subjects: 176
Study 9914663 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of positive interpersonal expectations
Number of subjects: 0
Study 9914663 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of negative interpersonal expectations
Number of subjects: 0
Study 9914663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically accessible interpersonal expectations (assessed by an attachment questionnaire)
Number of subjects: 0
Study 7818813 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen (100 micrograms or more)
Number of subjects: 48
Study 7818813 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen
Number of subjects: 48
Study 7818813 — intervention group
Group type: COMPARATOR
Intervention: Incomplete Freund's adjuvant (IFA)
Number of subjects: 48
Study 3243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week intensive cardiac rehabilitation programme
Number of subjects: 98
Study 3243304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 30926955 — intervention group
Group type: COMPARATOR
Intervention: IBT-liraglutide
Number of subjects: 113
Study 30926955 — intervention group
Group type: COMPARATOR
Intervention: Multi-component
Number of subjects: 113
Study 30926955 — intervention group
Group type: COMPARATOR
Intervention: IBT-alone
Number of subjects: 113
Study 29396153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition‐ and physical activity‐enhanced Parents as Teachers curriculum
Number of subjects: 54
Study 29396153 — intervention group
Group type: COMPARATOR
Intervention: Parents as Teachers curriculum
Number of subjects: 54
Study 29056859 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 5 μg/h titrated to 20 μg/h, once weekly for 6 weeks
Number of subjects: 87
Study 29056859 — intervention group
Group type: COMPARATOR
Intervention: Oral tramadol/acetaminophen (TA) 37.5 mg/325 mg, titrated to 4 tablets, twice daily for 6 weeks
Number of subjects: 87
Study 25777980 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive blocking
Number of subjects: 5
Study 25777980 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroactive unovershadowing
Number of subjects: 5
Study 25777980 — intervention group
Group type: COMPARATOR
Intervention: Secondary memory task
Number of subjects: 5
Study 25777980 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive unovershadowing
Number of subjects: 5
Study 24023492 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS plus PEG‐CS
Number of subjects: 264
Study 24023492 — intervention group
Group type: COMPARATOR
Intervention: 4‐L PEG
Number of subjects: 264
Study 21129718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment (atorvastatin 80 mg/day)
Number of subjects: 18885
Study 21129718 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose treatment (atorvastatin 10 mg/day in TNT and simvastatin 20 to 40 mg/day in IDEAL)
Number of subjects: 18885
Study 21129718 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 18885
Study 21129718 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 18885
Study 19920722 — intervention group
Group type: EXPERIMENTAL
Intervention: LidoDin cream
Number of subjects: 40
Study 19920722 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 40
Study 16510622 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 29
Study 16510622 — intervention group
Group type: EXPERIMENTAL
Intervention: BPAP
Number of subjects: 29
Study 14632858 — intervention group
Group type: EXPERIMENTAL
Intervention: TR group (undescended testicle)
Number of subjects: 13
Study 14632858 — intervention group
Group type: COMPARATOR
Intervention: Control group (inguinal hernia or appendicitis)
Number of subjects: 13
Study 11090260 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated algae-derived DHA oil (0.57 g DHA/day) and fungal-derived AA oil (0.26 g AA/day) for 4 weeks
Number of subjects: 24
Study 11090260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 24
Study 9323059 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1829
Study 9323059 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study 8457236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried garlic powder (Sapec) 900 mg
Number of subjects: 12
Study 8457236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2947095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 36
Study 2947095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30893271 — intervention group
Group type: EXPERIMENTAL
Intervention: CD101 3% gel applied intravaginally on days 1 and 2
Number of subjects: 126
Study 30893271 — intervention group
Group type: EXPERIMENTAL
Intervention: CD101 6% ointment applied intravaginally on day 1
Number of subjects: 126
Study 30893271 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole 150 mg on day 1
Number of subjects: 126
Study 29954403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge transitional care program (CCB program)
Number of subjects: 500
Study 29954403 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 500
Study 27436210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve grafting procedures
Number of subjects: 2351
Study 27436210 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient procedure
Number of subjects: 2351
Study 27436210 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer operative time
Number of subjects: 2351
Study 27436210 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse wound classifications
Number of subjects: 2351
Study 27436210 — intervention group
Group type: EXPERIMENTAL
Intervention: Any complications
Number of subjects: 2351
Study 25118610 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate plus calcium acetate as a phosphate binder (Mg group)
Number of subjects: 72
Study 25118610 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate alone (Ca group)
Number of subjects: 72
Study 25118610 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate plus calcium acetate (Mg group)
Number of subjects: 72
Study 22651892 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Coaching
Number of subjects: 103
Study 22651892 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Coaching
Number of subjects: 103
Study 22651892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Coaching
Number of subjects: 103
Study 22651892 — intervention group
Group type: COMPARATOR
Intervention: Best Effort Control
Number of subjects: 103
Study 20491838 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal bone loss
Number of subjects: 32
Study 20491838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-apical bone defect
Number of subjects: 32
Study 20491838 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant length dehiscence
Number of subjects: 32
Study 20491838 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant width dehiscence
Number of subjects: 32
Study 17703457 — intervention group
Group type: EXPERIMENTAL
Intervention: External quality control (EQC) for liquid-based cytology
Number of subjects: 13
Study 17703457 — intervention group
Group type: COMPARATOR
Intervention: ASCUS diagnosis
Number of subjects: 13
Study 16029914 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar vaccination
Number of subjects: 30
Study 16029914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial vaccination
Number of subjects: 30
Study 16029914 — intervention group
Group type: COMPARATOR
Intervention: Intra-muscular vaccination (control)
Number of subjects: 30
Study 11999549 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (61.8 mg of isoflavones)
Number of subjects: 23
Study 11999549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9803068 — intervention group
Group type: EXPERIMENTAL
Intervention: Biozole (generic fluconazole)
Number of subjects: 12
Study 9803068 — intervention group
Group type: COMPARATOR
Intervention: Diflucan (innovator fluconazole)
Number of subjects: 12
Study 7634882 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 322
Study 7634882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 322
Study 7634882 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 322
Study 7634882 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization with gum
Number of subjects: 322
Study 2233545 — intervention group
Group type: EXPERIMENTAL
Intervention: fancimef
Number of subjects: 49
Study 2233545 — intervention group
Group type: COMPARATOR
Intervention: quinine combined with fansidar
Number of subjects: 49
Study 678365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen and 0.93% halothane
Number of subjects: 22
Study 678365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen and 1.30% enflurane
Number of subjects: 22
Study 678365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen and 0.31% methoxyflurane
Number of subjects: 22
Study 678365 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen (control group)
Number of subjects: 22
Study 30576030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 235
Study 30576030 — intervention group
Group type: COMPARATOR
Intervention: Present‐Centered Therapy (PCT)
Number of subjects: 235
Study 30576030 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of diagnosis (both treatments)
Number of subjects: 235
Study 27810568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 70
Study 27810568 — intervention group
Group type: COMPARATOR
Intervention: Life Review (LR)
Number of subjects: 70
Study 27810568 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WC)
Number of subjects: 70
Study 25623883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon 2 g/day
Number of subjects: 95
Study 25623883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon 4 g/day
Number of subjects: 95
Study 25623883 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 5 mg/day
Number of subjects: 95
Study 23866185 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Model of the Logistic Clinical SYNTAX score
Number of subjects: 2627
Study 23866185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Model of the Logistic Clinical SYNTAX score
Number of subjects: 2627
Study 23866185 — intervention group
Group type: COMPARATOR
Intervention: Anatomical SYNTAX score
Number of subjects: 2627
Study 21704788 — intervention group
Group type: EXPERIMENTAL
Intervention: MCHS test
Number of subjects: 280
Study 21704788 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA fall risk scores
Number of subjects: 280
Study 21704788 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional balance and mobility tests
Number of subjects: 280
Study 21704788 — intervention group
Group type: EXPERIMENTAL
Intervention: MCHS and PPA scores
Number of subjects: 280
Study 21704788 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular squatting
Number of subjects: 280
Study 21704788 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength, single-leg stance ability, leaning balance
Number of subjects: 280
Study 19217890 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma betaine concentrations
Number of subjects: 16
Study 19217890 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma dimethylglycine concentrations
Number of subjects: 16
Study 19217890 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine betaine excretions
Number of subjects: 16
Study 19217890 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine dimethylglycine excretions
Number of subjects: 16
Study 19217890 — intervention group
Group type: COMPARATOR
Intervention: Plasma betaine
Number of subjects: 16
Study 19217890 — intervention group
Group type: COMPARATOR
Intervention: Plasma dimethylglycine and urine betaine
Number of subjects: 16
Study 17710804 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, applied once daily for 30 minutes, with 2-3 courses on average
Number of subjects: 60
Study 17710804 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for liver protection
Number of subjects: 60
Study 15998769 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/d
Number of subjects: 41
Study 15998769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11972164 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 mg
Number of subjects: 47
Study 11972164 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 mg
Number of subjects: 47
Study 11972164 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 mg
Number of subjects: 47
Study 11972164 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 100 mg
Number of subjects: 47
Study 10357421 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 expression in thyroid malignancies (papillary, follicular, and anaplastic carcinomas)
Number of subjects: 172
Study 10357421 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 expression in medullary carcinomas
Number of subjects: 172